Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC (AGN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Allergan : Presents Data From Seventeen Abstracts At The 2017 American Society For Dermatologic Surgery Meeting In Chicago

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 06:20pm CET

DUBLIN, Oct. 5, 2017 /PRNewswire/ -- Allergan (NYSE: AGN), a leading global pharmaceutical company, announced today that it will present 17 Allergan-supported abstracts at the 2017 American Society for Dermatologic Surgery (ASDS) meeting in Chicago, Illinois from October 5-8.

The meeting will be held at the Exhibit Hall, Riverside Center and the scheduled times (noted in local Central Time) of the Allergan presentations, titles and authors are as follows:

Real-World Use of ATX-101 Treatment for Reduction of Submental Fat: Final Data from CONTOUR

  • Authors: Beer K, Callender VD, Shridharani SM, Schlessinger J, Teller CF, Chen J, Gallagher CJ
  • Poster Presentation
  • Thursday, 10/7, 5:30- 7:00 PM

Improvements in Submental Contour Achieved With ATX-101 Treatment Are Maintained Over Time: 3-Year Follow-up of Subjects from the Phase 3 REFINE Trials

  • Authors: Humphrey S, Bhatia AC, Green LJ, Cohen JL, Green JB, Liu C, Somogyi C
  • Poster Presentation
  • Thursday, 10/5, 5:30- 7:00 PM

OnabotulinumtoxinA for Treatment of Moderate to Severe Horizontal Frontalis Lines and Glabellar Lines from the Subject's Perspective: Patient-Reported Satisfaction and Impact Outcomes from a Phase 3 Double-Blind Study

  • Authors: Dayan S, Ogilvie P, Rivkin ; Yoelin S, Ferrusi I
  • Poster Presentation
  • Thursday, 10/5, Noon- 7:00 PM; Friday, 10/6, 10:00 AM- 7:00 PM; Saturday, 10/7, 9:00 AM-2:00 PM

Simultaneous Treatment of Moderate to Severe Horizontal Frontalis Lines, Glabellar Lines, and Lateral Canthal Lines With OnabotulinumtoxinA from the Subject's Perspective: Patient-Reported Satisfaction and Impact Outcomes from a Phase 3 Double-Blind Study

  • Authors: Dayan S, Ogilvie P, Rivkin ; Yoelin S, Ferrusi I
  • Poster Presentation
  • Thursday, 10/5, Noon- 7:00 PM; Friday, 10/6, 10:00 AM- 7:00 PM; Saturday, 10/7, 9:00 AM-2:00 PM

Efficacy and Safety of OnabotulinumtoxinA for Treatment of Moderate to Severe Forehead Lines

  • Authors: Fagien S, Cohen JL, Coleman W, Monheit G, Carruthers J, Mao C, Vitarella D, Lei X, Hardas B
  • Poster Presentation
  • Thursday, 10/5, Noon- 7:00 PM; Friday, 10/6, 10:00 AM- 7:00 PM; Saturday, 10/7, 9:00 AM-2:00 PM

OnabotulinumtoxinA (Botox) Displays Superior Activity to IncobotulinumtoxinA Drug Product (Xeomin) in Multiple in Vitro and in Vivo Assays

  • Authors: Canty D, Le L, Wang J, Nicholson G, Brideau-Andersen A, Steward L, Jacky B, Broide R, Washburn M, Rupp D
  • Poster Presentation
  • Thursday, 10/5, Noon- 7:00 PM; Friday, 10/6, 10:00 AM- 7:00 PM; Saturday, 10/7, 9:00 AM-2:00 PM

The Psychological Impacts of Forehead, Glabellar, and Lateral Canthal Lines: Qualitative, Patient-Centered Studies

  • Authors: S Dayan, S Yoelin, K De Boulle, I Ferrusi
  • Oral Presentation
  • Thursday, 10/5, 5:05- 5:10 PM

Juvéderm Vollure XC Is Safe and Effective for Long-term Correction of Nasolabial Folds: Results from a Multicenter, Randomized, Controlled Study

  • Authors: Dayan S, Maas CS, Grimes PE, Beer K, Monheit G, Hardas B, Lin V
  • Oral Presentation
  • Saturday, 10/7, 10:30 AM-10:35 AM

VYC-17.5L is Effective for the Treatment of Static and Dynamic Radial Cheek Lines: Results from the BEAM Study

  • Authors: Ogilvie P, Fink B, Leys C, Godlewska S, Niforos F, Kerson G, Silberberg M
  • Poster Presentation
  • Thursday, 10/5, Noon- 7:00 PM; Friday, 10/6, 10:00 AM- 7:00 PM; Saturday, 10/7, 9:00 AM-2:00 PM

VYC-17.5L is Safe and Effective for Long-Term Correction of Nasolabial Folds: Results from a Multicenter, Randomized, Controlled Study

  • Authors: Dayan S, Maas CS, Grimes PE, Beer K, Monheit G, Hardas B, Lin V
  • Oral Presentation
  • Saturday, 10/7, 10:30 AM-10:35 AM

Lip and Perioral Enhancement With HA Dermal Fillers in Individuals With Skin of Color

  • Authors: Taylor s, Downie S, Shamban A, Few J, Schumacher A, Gallagher C
  • Poster Presentation
  • Thursday, 10/5, Noon- 7:00 PM; Friday, 10/6, 10:00 AM- 7:00 PM; Saturday, 10/7, 9:00 AM-2:00 PM

Maximizing Panfacial Aesthetic Outcomes: Findings and Recommendations from the HARMONY Study

  • Authors: Kaminer M, Cohen J, Narurkar A, Shamban A, Werschler W, Shumate G, Gallagher C
  • Oral Presentation
  • Thursday, 10/5, 11:35-11:40 AM

Differential Facial Aesthetic Treatment Considerations for Skin of Color Populations: African American, Asian and Hispanic

  • Authors: Boyd C, Chiu A, Montes JR, Narurkar V, Shumate GT, Gallagher CJ
  • Poster Presentation
  • Thursday, 10/5, Noon- 7:00 PM; Friday, 10/6, 10:00 AM- 7:00 PM; Saturday, 10/7, 9:00 AM-2:00 PM

Skin Laxity Is Unchanged Among ATX-101 Treatment Responders: Post hoc Analysis of Phase 3 Data

  • Authors: Fabi S, McDiarmid J, Benito-Ruiz J, Bass LS, Jones DH, Orejudos A, Gallagher CJ, Somogyi C
  • Podium Presentation
  • Saturday, 10/7, 10:15-10:20 AM

Reduction of Submental Fat Continues Beyond 28 Days After ATX-101 Treatment: Results from a Post hoc Analysis

  • Authors: Dover JS, Shridharani SM, Bloom JD, Gallagher CJ, Somogyi C
  • Featured In Program Book

Efficacy and Safety of OnabotulinumtoxinA for Moderate to Severe Forehead Lines in Subjects With Upper Facial Lines

  • Authors: De Boulle K, Werschler P, Gold MH, Bruce S, Sattler G, Ogilvie P, Mao C, Vitarella D, Lei S, Hardas B
  • Featured In Program Book

A Customized Approach for Arm Fat Reduction using Cryolipolysis

  • Authors: Rivers J, Ulmer M, Vestvik B, Santos S
  • Featured In Program Book

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model - Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline programs currently in development.

Allergan's success is powered by our more than 18,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016 and Allergan's Quarterly Report on Form 10-Q for the period ended June 30, 2017. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

© 2017 Allergan. All rights reserved. All trademarks are the property of their respective owners.

CONTACTS:
Allergan:
Investors:
Daphne Karydas
(862) 261-8006

Media:
Mark Marmur
(862) 261-7558

Ember Garrett
(714) 246-3525

View original content with multimedia:http://www.prnewswire.com/news-releases/allergan-presents-data-from-seventeen-abstracts-at-the-2017-american-society-for-dermatologic-surgery-meeting-in-chicago-300531887.html

SOURCE Allergan plc

Allergan plc published this content on 05 October 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 05 October 2017 16:19:03 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALLERGAN PLC
12/13 TEVA PHARMACEUTICAL INDUSTRIES : Fears of Israeli job cuts at Teva sparks call f..
12/12 ALLERGAN : Receives FDA Clearance For the CoolSculpting® Treatment To Improve Ap..
12/08 TEVA CONSIDERING CUTTING UP TO 10,00 : Bloomberg
12/08 TEVA CONSIDERING CUTTING UP TO 10,00 : Bloomberg
12/07 ALLERGAN : Migraine Leadership Recognized with Enrico Greppi Award for Excellenc..
12/07 EDITAS MEDICINE : BioCentury - Editas raises $50M follow-on
12/01 Tech firms tell patent court to ignore Allergan deal with tribe
11/30 ALLERGAN : to Present at the 2017 Citi Global Healthcare Conference
11/29DJALLERGAN : Health Care Up on Rotation Out of Tech -- Health Care Roundup
11/29 ALLERGAN : Migraine Leadership Recognized with Enrico Greppi Award for Excellenc..
More news
News from SeekingAlpha
03:17a BIOTECH ANALYSIS CENTRAL PHARMA NEWS : AbbVie And Roche Stellar Data, Aduro Pull..
12/13 CONATUS : Likely To Dash Ahead Of NASH Data
12/13 Top 10 Net Payout Yields For December 2017
12/13 YOUR DAILY PHARMA SCOOP : Omeros Potential, Portola's Setback, Proteostasis Soar..
12/12 EASE THOSE FROWN LINES : Revance's Impact On Allergan Overblown
Financials ($)
Sales 2017 15 894 M
EBIT 2017 7 658 M
Net income 2017 -6 486 M
Debt 2017 24 765 M
Yield 2017 1,69%
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 5,10x
EV / Sales 2018 5,06x
Capitalization 56 286 M
Chart ALLERGAN PLC
Duration : Period :
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 225 $
Spread / Average Target 33%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Robert A. Stewart Chief Operating Officer
Maria Teresa Hilado Chief Financial Officer
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC-20.10%56 286
JOHNSON & JOHNSON21.53%379 175
NOVARTIS12.01%218 773
PFIZER10.04%215 837
ROCHE HOLDING LTD.3.40%209 423
MERCK AND COMPANY-6.96%153 659